XETRA - Delayed Quote EUR

Valneva SE (AYJ.DE)

2.8240

-0.1660

(-5.55%)

As of 12:16:15 PM GMT+2. Market Open.

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

Saint Herblain (France) and Schlieren (Zurich), April 9, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2 infant safety and immunogenicity study of Shigella4V2 (S4V2), the world’s most clinically advanced tetravalent bioconjugate vaccine candidate against shi

GlobeNewswire 5 hours ago

INRLF

VALN
Exploring Three High Growth Tech Stocks In Europe

The European market has recently experienced significant declines, with the pan-European STOXX Europe 600 Index dropping 8.44% amid heightened trade tensions and economic uncertainty stemming from new U.S. tariffs. In this challenging environment, identifying high growth tech stocks in Europe requires a focus on companies that demonstrate resilience through innovation and adaptability to evolving market conditions.

Simply Wall St. yesterday

BLV.PA

PHAR

PHGUF
Valneva SE Shareholding Declaration - March 2025

VALNEVA Declaration of shares and voting rights March 31, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: April 3, 2025 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on which this change w

GlobeNewswire 5 days ago

INRLF

VALN
Is Valneva (VALN) the Best Performing NASDAQ Stock So Far in 2025?

We recently published a list of 11 Best Performing NASDAQ Stocks So Far in 2025. In this article, we are going to take a look at where Valneva (NASDAQ:VALN) stands against other best performing NASDAQ stocks so far in 2025. On March 29, T. Rowe Price portfolio manager Tony Wang appeared on CNBC’s ‘Closing Bell […]

Insider Monkey 7 days ago

VLA.PA
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above

With this extension, IXCHIQ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU). Saint Herblain (France), April 1, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Commission (EC) has granted marketing authorization in Europe for Valneva’s single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chiku

GlobeNewswire 7 days ago

INRLF

VALN
Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA

Saint Herblain (France), March 31, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) to potentially expand the use of its chikungunya vaccine, IXCHIQ®, currently approved in adults1, to adolescents aged 12 to 17 years in the UK. This submission follows the recent positive opinion of the European Medicine

GlobeNewswire 9 days ago

INRLF

VALN
Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program

Saint-Herblain (France), March 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces that it has filed a prospectus supplement as part of the renewal of its registration statement on Form F-3, filed on March 25, 2025 with the U.S. Securities and Exchange Commission (“SEC”) relating to its existing At-the-Market offering facility (the “ATM Program”), which was originally entered into in August 2022 and has not been uti

GlobeNewswire 13 days ago

INRLF

VALN
Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F

Saint-Herblain (France), March 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 24, 2025, of its 2024 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.25-0140 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC). Valneva’s 2024 Universal Registration Document – available in its entirety in French – includes the Company’s 2024 Annual Fina

GlobeNewswire 15 days ago

INRLF

VALN
Valneva outlays 40,000 vaccines to Réunion amidst chikungunya surge

Valneva will work with local health authorities and wholesalers on the French island territory to distribute the vaccines.

Pharmaceutical Technology 15 days ago

VLA.PA
Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion

Saint Herblain (France), March 24, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it is responding to the chikungunya outbreak that is rapidly intensifying in France’s Island of La Réunion with its vaccine IXCHIQ®. In agreement and with support from the local public health agency, the Agence Régionale de Santé La Réunion, Valneva will provide 40,000 doses starting early April, with an option to provide more, through distribution agreement

GlobeNewswire 16 days ago

INRLF

VALN
Valneva SE (INRLF) (FY 2024) Earnings Call Highlights: Strong Sales Growth and Strategic ...

Valneva SE (INRLF) reports robust sales growth and strategic advancements, while navigating regulatory delays and increased R&D expenses.

GuruFocus.com 19 days ago

VLA.PA
Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

Met 2024 growth targets for product sales (+13% vs 2023) and total revenues (+10% vs 2023)Strong year-end cash position of €168.3 million including sale of Priority Review Voucher1, successful private placement and 67% reduction in operating cash burnSubstantial clinical and regulatory progress in 2024; further data readouts, product approvals and label extensions anticipated in 20252025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&D investments

GlobeNewswire 20 days ago

INRLF

VALN
High Growth Tech Stocks In Europe For March 2025

As European markets navigate the complexities of U.S. trade policy uncertainty and fluctuating economic indicators, the STOXX Europe 600 Index recently snapped a 10-week streak of gains, reflecting broader investor caution despite positive developments in Germany's defense and infrastructure spending. In this environment, identifying high-growth tech stocks requires a focus on companies that demonstrate resilience and adaptability to shifting market dynamics while capitalizing on...

Simply Wall St. 30 days ago

INRLF

VALN

BKHT.DE
VALNEVA Declaration of shares and voting rights: February 28, 2025

VALNEVA Declaration of shares and voting rights February 28, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: March 5, 2025 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change

GlobeNewswire last month

INRLF

VALN
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

Saint-Herblain (France), March 3, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach and CFO Peter Bühler will present at the TD Cowen 45th Annual Health Care Conference, taking place March 3 - 5, 2025, in Boston, MA. Mr. Lingelbach and Mr. Peter Bühler will also meet with institutional investors during the Van Lanscho

GlobeNewswire last month

INRLF

VALN
Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®

If granted, IXCHIQ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending authorization of a label extension for IXCHIQ®, Valneva’s single-d

GlobeNewswire last month

INRLF

VALN
Valneva hits 2024 sales target but plans lower cash burn in 2025

Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.

Pharmaceutical Technology last month

VLA.PA
Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook

Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023)Strong year-end cash position of €168.3 millionSubstantial clinical and regulatory progress in 2024, leading to multiple anticipated data readouts, product approvals and label extensions in 20252025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&D investments with lower operating cash burn Saint-Herblain (France), February 18, 2025 – Valneva SE (Nasdaq: VALN;

GlobeNewswire last month

INRLF

VALN
Bavarian Nordic scoops FDA approval for chikungunya vaccine in adults and teens

Bavarian Nordic sets up a bout with Valneva’s Ixchiq, the former’s Vimkunya already having an edge in population reach.

Pharmaceutical Technology last month

BAVA.CO

VLA.PA
Shareholding declaration Valneva SE - January 2025

VALNEVA Declaration of shares and voting rights January 31, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: February 6, 2025 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on which this cha

GlobeNewswire last month

INRLF

VALN

Performance Overview

Return	AYJ.DE	CAC 40 (^FCHI)
YTD	+32.46%	-6.76%
1-Year	-24.97%	-14.50%
3-Year	-81.97%	+5.10%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Valneva SE (AYJ.DE)

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

Exploring Three High Growth Tech Stocks In Europe

Valneva SE Shareholding Declaration - March 2025

Is Valneva (VALN) the Best Performing NASDAQ Stock So Far in 2025?

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above

Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA

Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program

Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F

Valneva outlays 40,000 vaccines to Réunion amidst chikungunya surge

Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion

Valneva SE (INRLF) (FY 2024) Earnings Call Highlights: Strong Sales Growth and Strategic ...

Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

High Growth Tech Stocks In Europe For March 2025

VALNEVA Declaration of shares and voting rights: February 28, 2025

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®

Valneva hits 2024 sales target but plans lower cash burn in 2025

Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook

Bavarian Nordic scoops FDA approval for chikungunya vaccine in adults and teens

Shareholding declaration Valneva SE - January 2025

Performance Overview